Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca announces positive lung cancer trial data for Tagrisso

AstraZeneca announces positive lung cancer trial data for Tagrisso

18th July 2016

AstraZeneca has announced the findings of a new clinical trial demonstrating the benefits its drug Tagrisso can offer in the treatment of lung cancer.

Data from the phase III AURA3 study showed that the drug demonstrated superior progression-free survival results compared to standard platinum-based doublet chemotherapy when used as a second-line treatment among more than 400 patients.

The study aimed to evaluate the performance of Tagrisso among patients with EGFR T790M mutation-positive, locally-advanced or metastatic non-small cell lung cancer, whose disease had progressed following first-line EGFR tyrosine kinase inhibitor (TKI) therapy.

Its strong performance in terms of survival, response, disease control and duration of response rates meant the drug was able to meet its primary efficacy endpoints in the trial, while also demonstrating a safety profile consistent with previous studies.

Sean Bohen, executive vice president for global medicines development and chief medical officer at AstraZeneca, said: "The AURA3 results demonstrate the benefits of our science-led approach that enabled the rapid development of Tagrisso as a targeted treatment to address the most common cause of resistance to a first-generation EGFR-TKI for patients with metastatic EGFR-mutant lung cancer."

Tagrisso was approved in Europe for the treatment of EGFR T790M mutation-positive metastatic non-small cell lung cancer earlier this year.ADNFCR-8000103-ID-801821912-ADNFCR

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.